In:
Revista da Sociedade de Cardiologia do Estado de São Paulo, Revista da Sociedade de Cardiologia do Estado de Sao Paulo, Vol. 31, No. 4 ( 2021-09-10), p. 388-393
Abstract:
Ischemic heart disease is a pathological process resulting from the deposition of atherosclerotic plaques in the epicardial coronary arteries. Drug therapies and surgical or percutaneous interventions are potential options aimed at the stabilization or regression of coronary artery disease. In recent decades, several clinical trials have sought to clarify whether some interventional and therapeutic strategies, either isolated or combined, could in fact bring some clinical benefit to patients with chronic coronary syndrome. In this context, this article highlights two of the main investigations that impacted cardiology practice over the last years: ISCHEMIA and LoDoCo2. The ISCHEMIA study and its several subanalyses show us that revascularization strategies seem to be strongly determinant only for chronic coronary syndrome patients with angina pectoris, with a significant impact on their quality of life. The LoDoCo2 study, on the other hand, highlights colchicine as a promising drug in reducing cardiovascular outcomes, in individuals with chronic coronary syndrome, when added to optimized drug therapy. Keywords: Atherosclerosis; Drug Therapy; Percutaneous Coronary Intervention; Cardio- vascular Surgical Procedures; Prognosis
Type of Medium:
Online Resource
ISSN:
0103-8559
,
2595-4644
Uniform Title:
CHRONIC CORONARY SYNDROME: ISCHEMIA AND LODOCO2 TRIALS
DOI:
10.29381/0103-8559/20213104
DOI:
10.29381/0103-8559/20213104388-93
Language:
Unknown
Publisher:
Revista da Sociedade de Cardiologia do Estado de Sao Paulo
Publication Date:
2021
detail.hit.zdb_id:
2053601-X
Bookmarklink